Diligence memo · auto-generated · as of July 2, 2026

Rebound Therapeutics Corp

Rebound Therapeutics Corp has raised $20M over 2 rounds; too few niche peers to rank its valuation yet.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Rebound Therapeutics Corp operates in Pharma, based in IRVINE.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Rebound Therapeutics Corp has raised $20M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $16M on 2017-07-14.

Most recent recorded round closed around 2017-07-14.

Valuation (modeled)modeled

Provath models Rebound Therapeutics Corp at approximately $561M (range $35M–$2.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Historic cadence: a new round about every 19 months.

Last raise 9.0 yr ago; this sector typically re-raises about every 16 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 4.4× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 76% of Pharma peers (310 compared).

Modeled value ranks above 87% of those peers.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.